<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Oct. 14, 2020 (HealthDay News) — Enrollment in a study testing an experimental antibody therapy against COVID-19 has been paused by independent monitors.<\/p>\n
The study, ACTIV-3, was testing the use of a single antibody with the antiviral drug remdesivir. The antibody is being developed by Eli Lilly and the Canadian company AbCellera, the Associated Press<\/i> reported. The study has been paused “out of an abundance of caution,” Lilly said Tuesday, but the company did not explain what prompted the decision.<\/p>\n
The study is sponsored by the U.S. National Institute of Allergy and Infectious Diseases, which did not immediately comment, the AP<\/i> reported.<\/p>\n
After falling ill with COVID-19, President Donald Trump received an experimental two-antibody cocktail from Regeneron Pharmaceuticals Inc. Regeneron and Lilly are both seeking emergency use authorization from the FDA for their COVID-19 treatments while late-stage studies continue, the AP<\/i> reported.<\/p>\n
More Information<\/a><\/p>\n <\/i><\/p>\n Health News<\/a> Copyright \u00a9 2020 HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":" ACTIV-3 study, testing use of an antibody therapy with remdesivir, paused ‘out of an abundance of caution’<\/p>\n","protected":false},"author":4,"featured_media":1862,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[85],"tags":[97,100,125],"acf":[],"_links":{"self":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/1840"}],"collection":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/comments?post=1840"}],"version-history":[{"count":0,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/1840\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media\/1862"}],"wp:attachment":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media?parent=1840"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/categories?post=1840"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/tags?post=1840"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}